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Abstract
Background/Aims: Gluco-incretin hormones increase the glucose competence of pancreatic beta-cells by incompletely
characterized mechanisms.
Methods: We searched for genes that were differentially expressed in islets from control and Glp1r2/2; Gipr2/2 (dKO) mice,
which show reduced glucose competence. Overexpression and knockdown studies; insulin secretion analysis; analysis of
gene expression in islets from control and diabetic mice and humans as well as gene methylation and transcriptional
analysis were performed.
Results: Fxyd3 was the most up-regulated gene in glucose incompetent islets from dKO mice. When overexpressed in beta-
cells Fxyd3 reduced glucose-induced insulin secretion by acting downstream of plasma membrane depolarization and Ca++
influx. Fxyd3 expression was not acutely regulated by cAMP raising agents in either control or dKO adult islets. Instead,
expression of Fxyd3 was controlled by methylation of CpGs present in its proximal promoter region. Increased promoter
methylation reduced Fxyd3 transcription as assessed by lower abundance of H3K4me3 at the transcriptional start site and in
transcription reporter assays. This epigenetic imprinting was initiated perinatally and fully established in adult islets. Glucose
incompetent islets from diabetic mice and humans showed increased expression of Fxyd3 and reduced promoter
methylation.
Conclusions/Interpretation: Because gluco-incretin secretion depends on feeding the epigenetic regulation of Fxyd3
expression may link nutrition in early life to establishment of adult beta-cell glucose competence; this epigenetic control is,
however, lost in diabetes possibly as a result of gluco-incretin resistance and/or de-differentiation of beta-cells that are
associated with the development of type 2 diabetes.
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Introduction
The gluco-incretin hormones GLP-1 and GIP play multiple
roles in the control of glucose homeostasis, in part by acting on
pancreatic beta-cells. They potentiate glucose-induced insulin
secretion (GIIS) [1,2], induce beta-cell proliferation [3,4], protect
these cells against cytokine- or glucolipotoxicity-induced apoptosis
[5,6], and increase their glucose competence [7]. Their actions
depend on their binding to specific Gs protein-coupled receptors
[8,9], which induce the production of cAMP leading to activation
of protein kinase A, or of the cAMP binding protein Epac2 [10].
Intracellular signaling of the GLP-1 receptor also includes
interaction with b-arrestins [11–13]. An important component of
the action of GLP-1 is the induction of IGF-1R and IRS-2
expression and activation of the PI3K/Akt signaling pathway by
autocrine secretion of IGF-2 and its binding to the IGF-1R
[7,14,15].
Type 2 diabetes (T2DM) appears when insulin secretion is no
longer sufficient to compensate for peripheral insulin resistance.
This is caused by a reduced insulin secretion capacity and a
reduction in the total number of beta-cells [16]. Whereas in
T2DM patients GIP no longer stimulates insulin secretion GLP-1,
at pharmacological concentrations, can still acutely, and glucose-
dependently potentiate insulin secretion [17,18]. Newer strategies
for the treatment of T2DM therefore aim at increasing GLP-1
signaling. This approach depends on the acute stimulation of
insulin secretion and it is still uncertain whether the increase in
beta-cell mass and function observed in rodents also takes place in
humans. Current evidence rather suggests the opposite since
cessation of incretin therapy rapidly leads to re-appearance of
hyperglycemia [19]. It is not clear whether the apparent absence
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of trophic action on human islets is due to a late initiation of the
treatment when beta-cells are already severely dysfunctional or
whether human beta-cells respond to gluco-incretin hormones in a
different manner than rodent beta-cells. It is therefore important
to better understand the molecular action of gluco-incretins on
beta-cells.
In previous studies, we showed that islets from Gipr2/2; Glp-
1r2/2 (dKO) mice had reduced GIIS but normal insulin sensitivity
[20], increased susceptibility to cytokine-induced apoptosis [15],
and reduced glucose competence [7]. These defects were cell-
autonomous and maintained when islets were maintained in
in vitro cultures. Here, we identify Fxyd3 as the gene that is most
overexpressed in dKO islets. Fxyd3 belongs to the Fxyd family of
single transmembrane domain containing proteins. These are best
known as third subunits of the Na+/K+-ATPase, which can
change the affinity of the pump for either Na+ and/or K+ [21].
Fxyd3, also called Mat-8 [22], has a unique topology with two
transmembrane domains. It can also associate with the H+/K+-
ATPase, regulate hyperpolarization-activated chloride channels in
Xenopus oocytes [22], and its expression is required for the
differentiation of the intestinal CaCo2 cell line [23]. It is also
overexpressed and may control proliferation of different cancer
types [24,25]. In this study, we show that Fxyd3 is a negative
regulator of GIIS whose expression is negatively regulated by
gluco-incretin hormone-dependent promoter methylation, a con-
trol that is lost in islets from diabetic mice and humans leading to
Fxyd3 overexpression.
Research Design and Methods
Mice
C57BL/6J and Glp1r2/2; Gipr2/2 (dKO) mice backcrossed in
C57BL/6J background were used. Glp1r2/2 and Gipr2/2 and
dKO mice were littermates obtained by crossing Glp1r+/2; Gipr+/2
heterozygous mice. db/db and db/+ mice were from Janvier (Le
Genest/Isle, France). db/db and db/+ mice were 9 weeks old at the
time of experiments. Mice were killed by cervical dislocation after
isoflurane anesthesia. All experimental procedures received approv-
al from the Service Ve´te´rinaire du Canton de Vaud.
Antibodies
Rabbit anti-mouse Fxyd3 was a gift from Pr. K. Geering
(University of Lausanne). Goat anti-mouse immunoglobulin
antibodies (M-20) were from Santa Cruz Biotechnology (Nunnin-
gen, Switzerland); guinea pig anti-insulin antibodies (A0564) from
DAKO; rabbit anti-actin antibodies from Sigma (A2066).
Cell Culture
MIN6 cells were from Drs Miyazaki and maintained as
described [26]. For transient transfection they were seeded at
0.25.106 cells per well, transfected one day later with Lipofecta-
mine 2000 (Invitrogen, Carlsbad, CA) and used 48 h later. Stable
transfection was performed with recombinant lentiviruses and
G418 selection [27]. For secretion tests, 20 islets or 0.25.106 MIN6
cells were placed in 12-well plates; MIN6 cells were used 4 days
later. After a 2 h incubation in Krebs-Ringer bicarbonate HEPES
buffer (KRBH, 120 mM NaCl, 4 mM KH2PO4, 20 mM
HEPES, 1 mM MgCl2, 1 mM CaCl2, 5 mM NaHCO3, and
0.5% BSA, pH 7.4) containing 2 mM glucose the medium was
replaced with KRBH containing 2 or 20 mM glucose for one
hour. Insulin was determined by radioimmunoassay (Millipore,
Billerica, MA, USA). Intracellular calcium concentrations record-
ing were performed on stably transfected MIN6 cells as described
[28].
Primary islets studies
Adult islets were isolated as described [29]. Neonates islets were
handpicked from collagenase-digested pancreas. Immunofluores-
cence microscopy analysis of islets monolayers seeded on
extracellular matrix-coated plates (Novamed, Jerusalem, Israel)
was performed as described [29]. Adenoviral transductions of
dissociated islets (3 minutes at 37uC in a Hank’s balanced salt
solution, 5 mM glucose, 1 mM EGTA) were performed with
pAdGFP or pAdFxyd3 adenoviruses (AdEasy system [30]) with a
multiplicity of infection of 50. Assays were performed 48 h later.
Bisulfite sequencing
Islet DNA was extracted using the DNeasy Blood and Tissue kit
from Qiagen (Hilden, Germany). 500 ng of DNA were converted
using Epitect Bisulfite kit from Qiagen. Then, R1 (+84; 2362) and
R2 (–655; 21138) regions from the Fxyd3 promoter were PCR
amplified (for primers see Table S1) and sub-cloned into TOPO-
TA vector (Invitrogen, Carlsbad, CA, USA). Ten clones per region
and per mouse were then sequenced in both directions to assess
CpG methylation status.
Pyrosequencing
Six regions of the Fxyd3 promoter were PCR amplified
(Pyromark PCR kit from Qiagen) with one biotinylated primer
(see Table S1) starting from 30 ng of bisulfite-treated DNA.
Pyrosequencing was performed on a PSQ 96MA instrument
(Qiagen) using Pyromark Gold Reagents from Qiagen. For each
human sample 12 regions of the FXYD3 promoter were PCR
amplified and pyrosequenced. Primers (Table S2) were designed
with the Biotage PSQ Assay Design software and data were
analysed by the Pyro Q-CpG software (Qiagen).
Chromatin Immunoprecipitation
Islets were pooled from 4 adult mice per ChIP experiment
performed using minor modifications of the micro-ChIP protocol
[31]. Islets were lysed with 115 mL of lysis buffer (50 mM Tris-
HCl pH 8,0; 10 mM EDTA; 1% SDS; 1 mM PMSF; 20 mM
butyrate; protease inhibitors cocktail from Roche) during 20 min-
utes at 4uC. Samples were then sonicated 3x[20 sec ON/40 sec
OFF] and washed with RIPA ChIP buffer (10 mM Tris-HCl
pH 7,5; 1 mM EDTA; 1% TX-100; 0,1% SDS; 0,1% Na-
deoycholate; 100 mM NaCl; 1 mM PMSF; 20 mM butyrate;
protease inhibitors cocktail). 1 mg of anti-H3K4me3 (Diagenode,
Denville, NJ, USA) and 10 mL of agarose beads blocked with
sonicated salmon sperm (Millipore, Temecula, CA, USA cat#16–
157) were used per ChIP sample. After elution of DNA/Protein/
antibodies complexes, reversal of the crosslinking and proteinase
K/RNAse A treatment, DNA was purified using the NucleoSpin
kit from Macherey-Nagel (Duren, Germany). For primers used see
Table S1.
Luciferase assay
MIN6 cells were seeded at 0.15.106 cells per well in 24-well
plates. The day after plating, they were co-transfected with 30 ng
of Renilla luciferase vector and 750 ng of the firefly luciferase
reporter plasmids using Lipofectamine 2000 (Invitrogen). Firefly
and renilla luciferase activities were measured 48 h later with a
Glomax Instrument (Promega, Madison, WI, USA). The mouse
Fxyd3 promoter (–731 to +19) was cloned into pGL3basic vector
(Promega) or the pCpGLbasic, CpG-free vector (gift from Dr. M.
Rehli, Regensburg, Germany). In vitro methylation was per-
formed using SssI and S-adenosyl-methionine (SAM) (New
England Biolabs, Ipswich, MA, USA).
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Human islet microarray analysis
Human islet RNA was prepared from laser capture microdis-
sected samples and profiled by microarray analysis [32].
Statistical analysis
All experiments were performed at least three times. Results are
expressed as means +/2 sem. Comparisons were performed using
unpaired Student’s t test or one-way or two-way ANOVA for the
different groups followed by post hoc pair-wise multiple-compar-
ison procedures (Tukey test or Bonferroni, respectively).
Results
Fxyd3 overexpression in islets from dKO mice
Comparative transcriptomic analysis of islets from control and
dKO mice [15] revealed Fxyd3 as the most up-regulated mRNA in
mutant as compared to control islets (data not shown). Quantitative
RT-PCR (Figure 1A) and western blot analysis (Figure 1B) confirmed
a three-fold increase in Fxyd3 mRNA and protein expression in islets
from adult dKOmice and showed that expression was similar in islets
from control or single gluco-incretin receptor knockout mice (Glp1r2/
2 or Gipr2/2 mice). Immunofluorescence microscopy analysis
performed on dKO islet cell monolayers showed that FXYD3
expression was expressed at the cell surface (Figure 1C). Quantitative
RT-PCR analysis of all the members of the Fxyd family revealed
relatively high expression of Fxyd6, intermediate levels of Fxyd3, and
very low expression of the other isoforms (Figure 1D). Importantly,
only Fxyd3 was differentially expressed in islets from control as
compared to dKO mice. These data indicate that in the absence of
both gluco-incretin receptors there is a selective overexpression of
Fxyd3, which is correlated with decreased GSIS [20].
FXYD3 overexpression impairs glucose-stimulated insulin
secretion
To assess whether Fxyd3 overexpression impacts on insulin
secretion, we transiently co-transfected MIN6 cells with a Fxyd3
and a human growth hormone (hGH) expression plasmids or with
control vectors. The cells were then challenged with low (2 mM) or
Figure 1. Fxyd3 is overexpressed in dKO islets. (A) Fxyd3 mRNA level in primary islets from control (CTRL), dKO, Glp1r2/2 or Gipr2/2 mice. Data
are mean 6 sem, n = 4–5; **p,0,01, ***p,0,001. (B) Western blot analysis and quantification of Fxyd3 expression in primary islets from CTRL, dKO,
Glp1r2/2 and Gipr2/2 mice. Data are mean 6 sem, *p,0,05, n = 4–5. (C) Confocal immunofluorescence microscopy detection of insulin and Fxyd3 in
CTRL and dKO islets cultured on ECM plates. (D) Quantitative RT-PCR analysis of Fxyd family members expression in control and dKO islets. Data are
mean 6 sem n= 4–5, ***p,0,001 compared to CTRL.
doi:10.1371/journal.pone.0103277.g001
Gluco-Incretins Control Fxyd3 to Regulate Insulin Secretion
PLOS ONE | www.plosone.org 3 July 2014 | Volume 9 | Issue 7 | e103277
Figure 2. Fxyd3 overexpression impairs glucose stimulated insulin secretion in MIN6 cells and primary beta.-cells. (A) MIN6 cells were
transiently transfected with a control or Fxyd3 expression plasmid and a plasmid for expression of hGH. Secretion of hGH was then measured at the
indicated glucose concentrations. Data are mean 6 sem; n = 5 experiments realized in triplicates, ***p,0,001. (B) MIN6 cells stably transfected with a
control or Fxyd3 expressing construct were exposed to the indicated concentrations of glucose, KCl or the calcium channel agonist BayK8644. Insulin
and hGH secretions were measured in control and Fxyd3 over-expressing cells/islets in multiple experiments. A two-way anova with repeated
measurements (pairing each experiment) with post hoc Bonferroni test was used to compare the groups. Data are mean 6 sem, n= 10 experiments
realized in triplicates, *p,0,05 **p,0,01 ***p,0,001. (C) Western blot analysis of Fxyd3 expression in transiently or stably transfected MIN6 cells. (D,
E) Primary islets were isolated from control mice and infected either with LacZ or Fxyd3 adenoviruses. Islets were challenged with the indicated
glucose and KCl concentrations. Data are mean 6 sem; n = 7 experiments realized in triplicates; **p,0,01). (E) Western blot analysis of Fxyd3
expression in control and Fxyd3 adenoviruses infected islets. (F and G) Intracellular calcium concentrations measured using the Fura2 ratiometric
method. Stably control- or Fxyd3-transduced MIN6 cells were superfused with 2 or 20 mM glucose and 30 mM KCl as indicated. (J) Quantification of
the calcium response. Data are mean 6 sem, n = 20 per group.
doi:10.1371/journal.pone.0103277.g002
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high (20 mM) glucose concentrations and hGH secretion was
measured. High glucose concentrations induced a,3-fold increased
secretion rate in control cells and this was markedly lower in Fxyd3
overexpressing cells (Figure 2A). Separately, we established MIN6
cell lines expressing Fxyd3 or LacZ by lentiviral transduction.
Figure 2B shows that insulin secretion was reduced in Fxyd3
expressing as compared to control cells when stimulated by glucose,
by KCl, or by the calcium channel agonist BayK8644. The level of
Fxyd3 overexpression in transiently and stably transfected MIN6
cells is shown in Figure 2C; there was no detectable expression of
FXYD3 in non-transfected MIN6 cells. When recombinant
adenoviruses were used to transduce Fxyd3 or GPF in mouse islets
overexpression of Fxyd3 significantly impaired glucose- as well as
K+-induced insulin secretion (Figure 2D). Overexpression of Fxyd3
was verified by western blot analysis (Figure 2E). We next assessed
whether glucose-induced raise in intracellular Ca++ concentrations
was normal in Fxyd3 overexpressing cells. Figure 2F, G shows that
the intracellular calcium concentrations increased similarly in Ctrl
and Fxyd3 overexpressing MIN6 cells following a glucose challenge
or K+-induced depolarization. Together, these results indicate that
Fxyd3 overexpression indeed reduces stimulated insulin secretion
and that the defect in glucose signaling lays downstream of
membrane depolarization and calcium entry.
Fxyd3 expression is not acutely regulated by the cAMP/
PKA pathway
Since Fxyd3 is overexpressed when both gluco-incretin receptor
genes are inactivated we postulated that Fxyd3 expression could be
under negative regulation by the cAMP signaling pathway. We thus
tested expression of Fxyd3 in control or dKO islets treated with
forskolin for 7, 18 or 48 hours. Neither Fxyd3mRNA (Figure 3A, C)
nor protein (Figure 3B, D) expression was modified in these
conditions whereas the expected increased expression of the IGF-
1R was observed (Figure 3E). Treatment of control islets with
100 nM exendin-4 for the same periods of time did not modify Fxyd3
mRNA expression (not sown). Thus, these data indicate that
activation of the cAMP/PKA pathway does not acutely regulate
Fxyd3 expression in adult islets. Instead, they suggest that absence of
gluco-incretin signaling induces a permanent change in the regulation
of Fxyd3 gene expression. We thus evaluated whether the differential
expression of Fxyd3 in islets from dKO vs. control mice was already
present at birth or was established during postnatal development.
Fxyd3 expression was assessed in islets of 3–4 day-old mice and
compared to that of adult control and dKO mice (Figure 3F).
Expression of Fxyd3 was slightly higher in islets from neonatal dKO
as compared control mice, although the difference did not reach
statistical significance (p=0.07). However, whereas Fxyd3 expression
was reduced in islets from adult as compared to neonatal control
mice, no such reduction in expression was observed in the dKO islets.
Thus, Fxyd3 expression is normally suppressed in islets during
postnatal development by a gluco-incretin-dependent mechanism
distinct from the cAMP/PKA/CREBP transcriptional regulatory
pathway.
Methylation of the Fxyd3 promoter reduces gene
transcription
To determine whether this regulatory events depend on Fxyd3
promoter methylation, a mechanism of gene silencing [33,34], we
Figure 3. Fxyd3 expression is not regulated by exendin-4 or forskolin in adult islets. Primary islets from adult control (A, B) and dKO (C, D)
mice were incubated with DMSO (vehicle) or 10 mM forskolin (fsk) for the indicated periods of time after O/N rest. Then, RNA (A, C) or proteins (B, D)
were extracted for quantitative analysis of Fxyd3 expression. Data are mean6 sem, n = 3 to 4. (E) Induction of IGF1-R expression in control islets after
18 hours of forskolin treatment. (F) Fxyd3 is down-regulated during post-natal development in control but not in dKO islets. Neonates were 3 to 4
days-old. Data are mean 6 sem, n= 10 to 11 samples per group, ***p,0,001.
doi:10.1371/journal.pone.0103277.g003
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analyzed Fxyd3 promoter methylation using bisulfite conversion of
MeCpGs followed by sequencing. We analyzed two segments of
the mouse Fxyd3 promoter, the R1 region from 2362 to +84 and
the R2 region from 21138 to–665 (relative to the transcriptional
start site +1) (Figure 4A), which were found based on sequence
analysis (UCSC genome browser, http://genome.ucsc.edu/) to
contain 20 out of the 21 CpGs of this proximal promoter region.
Bisulfite conversion efficiency was assessed by measuring the
conversion rate of cytosines located outside of CpG sequences and
was found to be ,98%. Five CpG were differentially methylated
between control and dKO islets at positions 2699 (81% in Ctrl vs.
0% in dKO); 2280 (59% in Ctrl vs.22% in dKO); 2267 (53% in
Ctrl vs. 22% in dKO); 2250 (71% in Ctrl vs. 53% in dKO); 2219
(94% in Ctrl vs. 56% in dKO) (Figure 4A).
Figure 4. Differential methylation of the Fxyd3 promoter in control and dKO islets. (A) Upper part: schematic representation of the Fxyd3
promoter and the R1 and R2 regions that have been analyzed by sequencing following bisulfite conversion of cytosines. Lower part: schematic
representation of the cytosines that were methylated (black dots), not methylated (circles) or not determined (brown dots). (B, C) DNA was prepared
from control and dKO adult or neonates islets. Following bisulfite treatment, pyrosequencing was performed to quantitate the methylation of
individual CpGs. (B) Global promoter methylation in neonate and adult islets. These data were derived from the calculated means of the percent
methylated CpG at each position and for each group of mice. These means were compared for each position between groups using a two-way anova
with repeated measurements with post-hoc Tukey test. Data are mean 6 sem, n= 6–12 islet preparations; **p,0,01. (C) Quantitative methylation of
seven CpGs in islets of control and dKO neonate and adult mice. Data are mean 6 sem, n = 6–12 islet preparations; statistics are: #p,0.05 when
compared to CTRL neonates (white dashed bars); *p,0.05 when compared to CTRL adults (white bars); £ p,0.05 when compared to dKO neonates
(grey dashed bars) and $ p,0.05 when compared to dKO adults (grey bars).
doi:10.1371/journal.pone.0103277.g004
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To get quantitative information about the differential methyl-
ation of these sites, we used pyrosequencing analysis. Following
bisulfite conversion of adult and 3–4 day-old mouse islet genomic
DNA, 6 regions were PCR amplified using a biotinylated primer
and sequenced. Global methylation level of the Fxyd3 promoter
was the same in islets from control and dKO neonate mice
(Figure 4B). This methylation level was not changed during
development to the adult stage in dKO islets but was significantly
increased in control islets (Figure 4B). Detailed analysis of the
methylation patterns (Figure 4C) showed that seven CpGs (–699;
2446; 2280; 2267; 2250; 2219; 262) were significantly more
methylated in control than in dKO adult islets, and the CpGs at
positions 2699; 2446; 2280; 2219; 262 were more methylated
in adult as compared to neonate control islets. In dKO islets,
methylation of the CpGs at position2699,2280,2267,2250,2
62 was not increased when comparing islets from neonate and
adult mice; only those at position 2446 and 2219 were increased.
Thus, in the absence of gluco-incretin receptors a differential
methylation of the Fxyd3 promoter is already evident at 3–4 days
of age but is fully established in adult mice.
To determine whether the level of methylation of the Fxyd3
promoter correlates with transcriptional activity, we determined
the degree of association of H3K4me3, a mark of actively
transcribed genes [35], with the transcription start site (TSS) of the
Fxyd3 gene using chromatin immunoprecipitation (ChiP) assays.
Figure 5A shows a higher presence of H3K4me3 at the TSS of the
Fxyd3 gene in islets of dKO as compared to control mice.
Association of H3K4me3 with the Gapdh TSS was the same in
both types of islets. Thus lower methylation of the Fxyd3 promoter
in dKO islets correlated with increased transcriptional activity.
To get an independent evidence for the role of promoter
methylation in gene expression, we constructed a luciferase
transcriptional reporter plasmid. This comprised the 2731 to +
19 segment of the Fxyd3 promoter subcloned in front of the
minimal promoter of the PGL3 firefly luciferase vector. This part
of the Fxyd3 promoter contains all the differentially methylated
CpGs. When transfected in MIN6 cells, this reporter construct
induced a three-fold stimulation of luciferase activity (Figure 5B).
To determine whether methylation of this promoter sequence
would reduce transcriptional activity, we first sub-cloned the
Fxyd3 promoter sequence into the CpG-free vector pCpGLbasic.
This plasmid was then methylated in vitro and transfected into
MIN6 cells. Methylation markedly decreased luciferase activity
(Figure 5C).
Fxyd3 promoter methylation upon gluco-incretin
treatment and in diabetes in mouse and human islets
To get a direct assessment of the role of gluco-incretin in the
regulation of Fxyd3 promoter methylation in the neonates, we
injected d0 control mice once a day for seven consecutive days
with either exendin-9-39 to antagonize GLP-1 action, or with a
combination of exendin-4 and GIP. As shown in Figure 6A, gluco-
incretin treatment increased methylation of the CpGs at position
2699, 2280, and 2250. Thus, in vivo administration of gluco-
incretins in neonate mice further increased Fxyd3 promoter
methylation at sites that are differentially methylated between
control and KO islets, indicating a direct role of these hormones in
the epigenetic regulation of Fxyd3. This increased methylation
lead to a slight but not significant decreased of Fxyd3 mRNA
expression (Figure 6B, p = 0,09).
Next we determined Fxyd3 expression and promoter methyl-
ation in islets from db/+ and db/db mice. Fxyd3 mRNA was
overexpressed and pyrosequencing analysis showed significantly
lower global methylation of the Fxyd3 promoter in islets from db/
db as compared to db/+mice (Figure 6C, D). When focusing on the
seven CpGs analyzed above (Figure 4D), we found that 4 of them
(at positions 2699; 2446; 2219 and 262) showed decreased
methylation in diabetic conditions (Figure 6E). Thus, an increase
in Fxyd3 expression, caused by promoter undermethylation, may
explain part of the secretion defect.
Finally, to determine whether Fxyd3 was also expressed in
human islets and whether its expression was regulated in type 2
diabetes, we assessed Fxyd3 expression by microarray and qRT-
PCR analysis. Figure 6F, G shows that Fxyd3 expression,
determined by microarray analysis using two different probesets,
was increased in islets from type 2 diabetic patients as compared to
control individuals. This was confirmed by quantitative PCR
analysis using a separate set of diabetic and control islets
(Figure 6H). For each of the 32 CpGs (Table S2) found in the
1.2 kb proximal promoter of human Fxyd3 we analyzed the
Figure 5. Hypermethylation of the Fxyd3 promoter reduces transcriptional activity. (A) ChIP analysis using H3K4me3 antibody reveals
enrichment in this histone mark at the transcriptional start site of the Fxyd3 gene in dKO as compared to control islets. Results are expressed as
percent of total input. Data are mean6 sem, n = 3 experiments, *p,0,05. (B) Luciferase activity measured in MIN6 cells transfected with a basic pGL3
or a Fxyd3promoter-PGL3 reporter construct. Data are mean 6 sem, n = 7 experiments realized in triplicates, ***p,0,001. (C) The same sequence of
the mouse Fxyd3 promoter was sub-cloned into the pCpGL vector (free of CpG). Following in vitro methylation (grey bar) or mock treatment (white
bar), basic or Fxyd3promoter-pCpGL plasmids were transfected into MIN6 cells and luciferase activity was measured 48 h later. Methylation
significantly reduces luciferase activity. Data are mean 6 sem, n = 3 experiments realized in triplicates, **p,0,01. (B, C) Plasmids were co-transfected
each time with Renilla reporter vector for normalization.
doi:10.1371/journal.pone.0103277.g005
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correlation between their methylation and the level of Fxyd3
mRNA expression. This analysis yielded significant correlation for
7 of these CpGs, all located in the proximal promoter region (–535
to 243) (Table 1). Importantly, 2 of these methylated CpGs, at
positions 2177 and 243, were highly correlated with Fxyd3
expression only in diabetic islets (Figure 6I and Table 1).
Discussion
Here, we show that gluco-incretin hormones regulate the
expression of Fxyd3, a newly identified regulator of beta-cell
glucose competence, by controlling the methylation its promoter.
This epigenetic imprinting is established perinatally and partially
lost in glucose incompetent islets from diabetic mice and humans,
which display increased expression of Fxyd3. Thus, gluco-incretin
action early in life contributes to the establishment of the normal
insulin secretion capacity of adult islets; loss of this imprinting may
contribute to the pathogenesis of type 2 diabetes.
Fxyd3 is a member of the FXYD family of proteins known to
regulate ion transporting membrane proteins, which can modulate
cellular differentiation, and whose expression is strongly up-
regulated in some tumors, making it a good cancer biomarker
[21,23] [36–39]. Why overexpression of Fxyd3 in beta-cells
reduces glucose-stimulated insulin secretion is not yet know. This
may be based on the interaction of Fxyd3 with membrane proteins
Figure 6. Fxyd3 promoter methylation in neonates and in diabetic mouse and human islets. (A) Ctrl neonates received daily injections for
7 days of Ex9–39 (2,5 nmol/kg) or Ex4 (2,5 nmol/kg) and GIP (80,4 nmol/kg). Methylation of CpG sites was determined by pyrosequencing. Data are
mean 6 sem, n = 3 experiments, *p,0,05, **p,0,01 as compared to control. (B) Fxyd3 mRNA expression in islets prepared as in (A). Data are mean6
sem, n= 4 experiments. (C) Fxyd3 mRNA expression in islets from db/+ and db/db mice. These data were derived from the calculated means of the
percent methylated CpG at each position and for each group of mice. These means were compared for each position between groups using a paired
t-test. Data are mean 6 sem, n = 4, *p,0,05. (D) Pyrosequencing analysis of global Fxyd3 promoter methylation in islets from db/+ and db/db mice.
Data are mean6 sem, n = 4, **p,0,01. (E) Pyrosequencing analysis of the methylation of individual CpGs. Data are mean6 sem, n = 4, *p,0,05, **p,
0,01, ***p,0,001. (E, F) FXYD3 expression in human islets assessed by Affymetrix chip analysis (F), probeset g13528881_3p_a_at; (G), probeset
g11612675_3p_a_at. Data are mean 6 sem, n = 10 per group, **p,0,01 and ***p,0,001 compared to controls. (H) FXYD3 mRNA expression
measured by real-time PCR using a separate set of control (n = 8 donors) and T2D (n = 8 donors) humans islets. Data are mean 6 sem, *p,0,05. (I)
Inverse correlation of CpG -43 methylation and Fxyd3 expression in islets from Ctrl and T2DM patients.
doi:10.1371/journal.pone.0103277.g006
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controlling beta-cell electrical activity or insulin granule exocytosis.
Additional work will clearly be required to answer this question.
We found Fxyd3 to be overexpressed in islets from dKO mice
and to negatively regulate glucose competence of insulin secreting
cells. Due to the limited information available on Fxyd3 function,
we further focused our attention on the unexpected mechanism by
which gluco-incretins regulate Fxyd3 expression. Indeed, forskolin
treatment, which induces marked accumulation of cAMP in
primary beta-cells, did not impact Fxyd3 expression in dKO nor in
control islets. Second, overexpression of Fxyd3 in dKO islets was
cell-autonomous and maintained in in vitro cultured islets
indicating a permanent change in gene expression. Thus, the
classical cAMP/PKA signaling pathway that acutely controls gene
expression through phosphorylation of CREBP was unlikely to be
involved in regulating Fxyd3 expression in adult islets. In neonatal
islets, Fxyd3 expression was slightly higher in dKO than in control
islets and this initial level of expression was maintained in islets
from adult dKO mice but markedly reduced in those of control
mice. We therefore suspected that absence of gluco-incretin
signaling involved a change in epigenetic control of Fxyd3
expression. Analysis of Fxyd3 promoter methylation revealed
differential methylation of seven CpGs in islets from adult control
as compared to dKO mice. Chromatin immunoprecipitation
analysis showed enrichment of H3K4me3 at the transcriptional
start site of Fxyd3 in dKO islets confirming higher transcriptional
activity. The inverse relationship between promoter methylation
and transcription rate was further supported by the Fxyd3
promoter reporter assays.
In neonatal islets, the difference in Fxyd3 promoter methylation
was already present at most sites. Importantly, however, the
difference in CpG methylation in control vs. dKO islets markedly
increased during the neonatal to adult transition at positions
2699, 2280, 2219, 262, suggesting that methylation of these
sites strongly influenced Fxyd3 transcription rate. Thus, this gluco-
incretin-dependent methylation of the Fxyd3 promoter takes place
in the perinatal period and is fully established in the adult animals.
With respect to the timing of this methylation events, it is
interesting to note that intestinal GLP-1 and GIP producing cells
appear first at embryonic day 15 (E15), rapidly increase in number
at E17, with both peptides being often co-expressed in the same
cells [40]. In addition, GLP-1 receptor has an intrinsic signaling
activity even in the absence of ligand [41]. Thus, gluco-incretins
and their receptors can influence beta-cells during embryonic
development and in the perinatal period. In addition, since these
methylation events occur perinatally in response to gluco-incretin
action, changes in hormonal and nutritional status during
pregnancy or early in life may have long-term impact on beta-
cell function and the susceptibility to develop diabetes in the adult
age.
Epigenetic regulation of gene expression by nutrition and
metabolic status is known to modulate the activity of multiple
cellular pathways [42]. Nutrition during pregnancy can impact
gene expression in offsprings through changes in DNA methyla-
tion [43] and similar effects of nutrition during the postnatal
period on the susceptibility to develop metabolic disease in the
adult age has also been linked to epigenetic modifications [44]. In
humans, it has been shown that islets from type 2 diabetic patients
display numerous changes in gene methylation patterns [45], and
that, in muscle, diabetes is associated with hypermethylation of the
Pgc1A promoter and lower gene expression leading to reduced
mitochondrial content [46]. Thus, whereas it is well established
that DNA methylation regulates gene expression, our study
uncovers a so far unrecognized role of gluco-incretins in epigenetic
regulation of gene expression that takes place early in life. This
could explain preceding observations that administration of GLP-
1 to diabetes-prone rats during the first week of life protected them
against the development of diabetes in their adult life [47,48].
Although the mechanism of this protection was not established, it
may involve epigenetic control of beta-cell function as reported
here.
Interestingly, we found that Fxyd3 expression was also increased
in glucose-unresponsive beta-cells from diabetic mice and humans
and that this was correlated with reduced methylation of the Fxyd3
promoter. In db/db mice three of the four sites that were
differentially methylated during maturation of adult islets (posi-
tions 2699, 2219 and 262), and which we propose may have a
particularly important role in controlling Fxyd3 expression,
displayed significantly reduced methylation. This suggests that
the methylation of these sites may be dynamically controlled by
gluco-incretin action. Indeed, type 2 diabetes is characterized by
beta-cell gluco-incretin resistance [49–51], which may explain the
reduced methylation and increased expression of Fxyd3. Alterna-
tively, it has been reported that diabetic hyperglycemia caused
beta-cell dedifferentiation as revealed by over expression of
transcription factors and enzymes normally present in precursor
Table 1. Correlation between FXYD3 expression and percent of methylation of individual CpGs.
All subjects Controls T2D patients
CpGposition r coeff p value r coeff p value r coeff p value
–43 –0,7219 0,0016 –0,7143 0,0576 –0,9048 0,0046
–177 –0,7353 0,0012 –0,6667 0,0831 –0,9286 0,0022
–197 –0,5588 0,0244
–230 –0,6265 0,0094
–391 –0,5412 0,0304
–452 –0,5029 0,0471
–535 –0,5971 0,0146
DNA from control (n = 8) and T2D (n = 8) human islets were extracted from the same samples as used for the real-time PCR analysis. Then, the 32 CpGs of the FXYD3
promoter from21 to21200 were analyzed by pyrosequencing. Correlation analysis between methylation level and FXYD3 expression measured by quantitative RT-PCR
was performed for each CpG using the non-parametric Pearson test. 7 CpG sites in the proximal FXYD3 promoter showed significant correlation between methylation
level and FXYD3 expression. Within these 7 CpGs, 2 sites showed strongly significant correlation between methylation and FXYD3 mRNA expression only in the T2D
group.
doi:10.1371/journal.pone.0103277.t001
Gluco-Incretins Control Fxyd3 to Regulate Insulin Secretion
PLOS ONE | www.plosone.org 9 July 2014 | Volume 9 | Issue 7 | e103277
cells [52,53]. Our data suggest that this may be accompanied by
changes in DNA methylation.
It is not yet clear how gluco-incretins control DNA methylation.
In mammals three DNA methyl transferases (Dnmts) catalyze the
addition of methyl groups on CpGs [33]. Dnmt1 is responsible for
propagation of methylation patterns through cell division cycles. In
beta-cells, this enzyme is also required to silence the expression of
the transcription factor Arx to prevent their differentiation into
alpha cells [54]. Dnmt3a and 3b catalyze de novo methylation.
Dnmts expression levels did not differ significantly in islets from
dKO or Ctrl mice (not shown). Thus, a modulation of their
activity by posttranslational modifications, as reported for Dnmt1
[55,56], rather than changes in expression levels may control the
methylation patterns.
In summary, we have identified Fxyd3 as a novel regulator of
beta-cell glucose competence. We showed that its expression is
controlled at the transcriptional level by gluco-incretin hormone-
dependent methylation of its promoter. This epigenetic regulation
is initiated in the perinatal period. As secretion of gluco-incretin
hormones is controlled by nutrients, the mechanism we describe
may link changes in early nutrition to long-term control of beta-
cell function. Because this epigenetic regulation is reversed in
glucose-unresponsive islets from diabetic mice and humans, which
express higher levels of Fxyd3, loss of imprinting of this locus may
contribute to beta-cell dysfunction characteristic of type 2 diabetes.
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